DCSIMG
Go
NIH Guidelines – Low-Dose ICS (Adults)

According To NIH Guidelines, Low-Dose Inhaled Corticosteroids (ICS) Are The Preferred Daily Treatment Option For Patients With Mild Persistent Asthma(1)

Stepwise approach for managing asthma in youths > 12 years of age and adults

aOngoing assessment of asthma control is recommended and daily treatment can be stepped up or down based on the patient's response to treatment.

bAlternative treatments are also available for daily medication per NIH Guidelines.

cPer NIH Guidelines, omalizumab may be considered as adjunctive therapy to high-dose ICS and long-acting ß2 agonist for patients who have allergies.

Adapted from NIH Guidelines for the Diagnosis and Management of Asthma; 2007.

  • NIH Guidelines define intermittent asthma as daytime symptoms ≤2 days/week; nighttime awakenings ≤2 nights/month; short-acting beta2 agonist (SABA) use ≤2 days/week; no interference with normal activity; normal FEV1 between exacerbations; FEV1 >80% predicted; normal FEV1/FVC; and 0 to ≤1 exacerbations per year that require oral systemic corticosteroids1